Insider Selling: Moderna Inc (NASDAQ:MRNA) CEO Sells $747,924.66 in Stock

Moderna Inc (NASDAQ:MRNA) CEO Stephane Bancel sold 11,046 shares of the stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $67.71, for a total transaction of $747,924.66. Following the completion of the transaction, the chief executive officer now owns 6,663,868 shares of the company’s stock, valued at $451,210,502.28. The sale was disclosed in a document filed with the SEC, which is available through this link.

Stephane Bancel also recently made the following trade(s):

  • On Monday, September 21st, Stephane Bancel sold 8,587 shares of Moderna stock. The stock was sold at an average price of $68.56, for a total transaction of $588,724.72.
  • On Wednesday, September 16th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $67.69, for a total transaction of $609,210.00.
  • On Friday, September 11th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $58.42, for a total transaction of $645,307.32.
  • On Friday, September 4th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $61.87, for a total transaction of $683,416.02.
  • On Wednesday, September 2nd, Stephane Bancel sold 18,247 shares of Moderna stock. The stock was sold at an average price of $63.22, for a total transaction of $1,153,575.34.
  • On Wednesday, August 26th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $67.45, for a total transaction of $607,050.00.
  • On Thursday, August 20th, Stephane Bancel sold 27,824 shares of Moderna stock. The stock was sold at an average price of $67.46, for a total transaction of $1,877,007.04.
  • On Thursday, August 13th, Stephane Bancel sold 19,000 shares of Moderna stock. The stock was sold at an average price of $72.22, for a total transaction of $1,372,180.00.
  • On Monday, August 10th, Stephane Bancel sold 19,143 shares of Moderna stock. The shares were sold at an average price of $74.23, for a total transaction of $1,420,984.89.
  • On Wednesday, August 5th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $77.49, for a total transaction of $697,410.00.

MRNA opened at $65.17 on Friday. The company has a market cap of $25.72 billion, a price-to-earnings ratio of -46.55 and a beta of 0.47. The company’s 50 day moving average is $66.87 and its 200 day moving average is $57.30. Moderna Inc has a 12-month low of $13.53 and a 12-month high of $95.21.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.05. The company had revenue of $66.35 million for the quarter, compared to the consensus estimate of $24.24 million. Moderna had a negative net margin of 461.42% and a negative return on equity of 27.85%. The company’s revenue was up 407.2% on a year-over-year basis. As a group, research analysts predict that Moderna Inc will post -1.54 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bessemer Group Inc. purchased a new position in shares of Moderna in the second quarter worth approximately $27,000. Corbenic Partners LLC purchased a new position in shares of Moderna in the second quarter worth approximately $32,000. BDO Wealth Advisors LLC purchased a new position in shares of Moderna in the second quarter worth approximately $32,000. Global Wealth Management Investment Advisory Inc. boosted its holdings in shares of Moderna by 124.0% in the second quarter. Global Wealth Management Investment Advisory Inc. now owns 560 shares of the company’s stock worth $36,000 after buying an additional 310 shares during the last quarter. Finally, Pacitti Group Inc. lifted its holdings in Moderna by 175.6% during the second quarter. Pacitti Group Inc. now owns 620 shares of the company’s stock valued at $44,000 after purchasing an additional 395 shares in the last quarter. 55.04% of the stock is currently owned by institutional investors.

MRNA has been the subject of a number of analyst reports. BMO Capital Markets raised their price objective on shares of Moderna from $94.00 to $112.00 and gave the company an “outperform” rating in a research note on Monday, July 27th. SVB Leerink restated a “sell” rating and set a $41.00 price objective on shares of Moderna in a research note on Thursday. Bank of America reduced their price objective on shares of Moderna from $80.00 to $75.00 in a research note on Wednesday, June 3rd. Brookline Capital Management restated a “buy” rating and set a $95.00 price objective on shares of Moderna in a research note on Monday, July 13th. Finally, Needham & Company LLC initiated coverage on shares of Moderna in a research note on Wednesday, August 5th. They set a “buy” rating and a $94.00 price objective for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $87.44.

About Moderna

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Recommended Story: What is a front-end load?

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.